Cargando…
TKI耐药后针对T790M突变治疗
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) the development of orally activesmall molecule inhibitors for non-small cell lung cancer (NSCLC) provides anew treatment plan. EGFR gene mutation in patients with activation EGFR tyrosine kinase inhibitor (EGFR-TKIs) therapy for the t...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000286/ https://www.ncbi.nlm.nih.gov/pubmed/25936890 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.04.10 |